Literature DB >> 28572259

Emerging Data and Current Challenges for Young, Old, Obese, or Male Patients with Breast Cancer.

Rachel A Freedman1, Ann H Partridge2.   

Abstract

There are distinct subgroups of patients who have historically been underrepresented in most prospective clinical trials in breast cancer, including the youngest and oldest patients, male patients, and those struggling with obesity. Herein, we review current and future directions in research for each of these special populations with breast cancer, highlighting significant knowledge gaps and priorities in tumor biology and heterogeneity, therapeutic decision making promotion of adherence, supportive care, and psychosocial and functional well-being. In younger women, future study should focus on the biological underpinnings of aggressive disease and optimizing adherence and treatment decision making while addressing their unique survivorship needs. The latter includes generating a scientific basis for interruption of therapy for pregnancy. Among older patients, interventions should focus on increasing clinical trial accrual, predicting and mitigating toxicity so that functional status can be optimized, tailoring needs for dose modification, and anticipating life expectancy in the context of competing causes of death. For men with breast cancer, we need worldwide collaboration to answer even basic questions on optimal treatment, supportive care, and survivorship strategies. Finally, for those struggling with obesity, we need to better understand the biological associations with cancer incidence, prognosis and outcome, and how we can best intervene to assure weight loss at the "right time." It is only through highly collaborative, far-reaching, prospective, multidisciplinary, patient-centered, and patient-engaged efforts that we can optimize the physical and psychologic outcomes for all patients with breast cancer. Clin Cancer Res; 23(11); 2647-54. ©2017 AACRSee all articles in this CCR Focus section, "Breast Cancer Research: From Base Pairs to Populations." ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 28572259     DOI: 10.1158/1078-0432.CCR-16-2552

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

1.  Radiomics Analysis of MRI for Predicting Molecular Subtypes of Breast Cancer in Young Women.

Authors:  Qinmei Li; James Dormer; Priyanka Daryani; Deji Chen; Zhenfeng Zhang; Baowei Fei
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2019-03-13

2.  Mutational Signatures in Breast Cancer: The Problem at the DNA Level.

Authors:  Serena Nik-Zainal; Sandro Morganella
Journal:  Clin Cancer Res       Date:  2017-06-01       Impact factor: 12.531

3.  Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?

Authors:  Ann H Partridge; Lisa A Carey
Journal:  Clin Cancer Res       Date:  2017-06-01       Impact factor: 12.531

Review 4.  Breast cancer in an 18-year-old female: A fatal case report and literature review.

Authors:  Maciej Jóźwik; Renata Posmyk; Marcin Jóźwik; Andrzej Semczuk; Magdalena Gogiel-Shields; Marta Kuś-Słowińska; Magdalena Garbowicz; Mark Klukowski; Jacek Wojciechowicz
Journal:  Cancer Biol Ther       Date:  2018-07-03       Impact factor: 4.742

5.  Management of young women with early breast cancer.

Authors:  Francesca Poggio; Matteo Lambertini; Claudia Bighin; Benedetta Conte; Eva Blondeaux; Alessia D'Alonzo; Chiara Dellepiane; Francesco Boccardo; Lucia Del Mastro
Journal:  ESMO Open       Date:  2018-11-14

6.  Prognostic Factors and Models for Elderly (≥70 Years Old) Primary Operable Triple-Negative Breast Cancer: Analysis From the National Cancer Database.

Authors:  Zhuowei Tang; Yuzhu Ji; Yu Min; Xiaohong Zhang; Weiyun Xu; Lijuan Zhao; Jing Zhang; Li Long; Jing Feng; Yixue Wen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-17       Impact factor: 5.555

7.  Comparisons of Metastatic Patterns, Survival Outcomes and Tumor Immune Microenvironment Between Young and Non-Young Breast Cancer Patients.

Authors:  Hengwen Sun; Wei Huang; Fei Ji; Yi Pan; Lu Yang
Journal:  Front Cell Dev Biol       Date:  2022-07-14

8.  Safety and efficacy of spleen aminopeptide oral lyophilized powder for improving quality of life and immune response in patients with advanced breast cancer: a multicenter, randomized, double-blind, placebo-controlled clinical trial.

Authors:  Jing Wang; Xiao Ma; Kun Shang; Shanshan Wu; Yan Ma; Zhongjun Ma; Bangwei Cao
Journal:  Anticancer Drugs       Date:  2021-11-01       Impact factor: 2.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.